To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00150176
Recruitment Status : Completed
First Posted : September 8, 2005
Results First Posted : May 28, 2010
Last Update Posted : October 30, 2015
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

September 2, 2005
September 8, 2005
April 28, 2010
May 28, 2010
October 30, 2015
April 2005
June 2008   (Final data collection date for primary outcome measure)
Time to Relapse or an Impending Relapse [ Time Frame: time of first relapse up to Day 182 (double blind phase) ]
A relapse or impending relapse was declared if a subject meets 1 of 3 "symptomatic relapse criteria" which were all based on a combination of the Positive and Negative Syndrome Scale (PANSS) total score or PANSS items, and Clinical Global Impression-Severity (CGI-S); or if in the opinion of the investigator, the subject's symptoms of schizophrenia had deteriorated to such an extent or the risk of violence to self or others or risk of suicide had increased so that certain prespecified measures were necessary.
Improvement in time to relapse in schizophrenic population
Complete list of historical versions of study NCT00150176 on Archive Site
Time to Early Discontinuation for Any Reason [ Time Frame: time of discontinuation up to Day 182 (double blind phase) ]
The number of days to early discontinuation is the number of days from randomization to early discontinuation from the study for adverse event, relapse or impending relapse that was not considered an adverse event, withdrawal of informed consent, or lost to follow-up (without evidence of relapse).
Not Provided
Not Provided
Not Provided
To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)
A Randomized, Placebo-Controlled, Double-Blind Trial of Asenapine in the Prevention of Relapse After Long-Term Treatment of Schizophrenia
Schizophrenia is a brain disease. The condition may be associated with acute psychotic episodes and long-term disability despite remission from the acute symptoms. Current management of schizophrenia focuses on the treatment of acute symptoms as well as long-term treatment aimed at preventing relapse after patients have experienced an improvement in acute symptoms. Patients who discontinue treatment have a high likelihood of experiencing relapse within 1-2 years after an acute episode of schizophrenia. Patients who remain on antipsychotic treatment have lower rates of relapse and have milder courses of exacerbation when relapse occurs.The symptoms of schizophrenia may be due to an imbalance in chemicals in the brain, primarily dopamine and serotonin, which enables brain cells to communicate with each other. Asenapine may help to correct the imbalance in dopamine and serotonin. The purpose of this clinical trial is to evaluate the efficacy of asenapine in preventing relapse/impending relapse (hereafter referred to as 'relapse') in subjects who have been treated with asenapine for symptoms of schizophrenia for 26 weeks. In addition, to determine the safety and tolerability of asenapine for up to 1-year of treatment.
Not Provided
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
  • Drug: Asenapine - Open Label
    Open Label Phase: All subjects received 26 weeks of open label asenapine treatment (cross titration period up to first 4 weeks, with target dose of 10 mg twice daily by week 1).
    Other Name: Saphris, Org 5222, SCH 900274
  • Drug: Placebo - Double Blind
    Double Blind Phase: Following Open Label Phase, matching placebo sublingual twice daily for 26 weeks.
  • Drug: Asenapine - Double Blind
    Double Blind Phase: Following the Open Label Phase, asenapine 5 or 10 mg sublingual twice daily for 26 weeks.
    Other Name: Org 5222, SCH 900274, Saphris
  • Experimental: asenapine
    • Drug: Asenapine - Open Label
    • Drug: Asenapine - Double Blind
  • Placebo Comparator: placebo
    • Drug: Asenapine - Open Label
    • Drug: Placebo - Double Blind
Kane JM, Mackle M, Snow-Adami L, Zhao J, Szegedi A, Panagides J. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiatry. 2011 Mar;72(3):349-55. doi: 10.4088/JCP.10m06306. Epub 2011 Feb 22.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
July 2008
June 2008   (Final data collection date for primary outcome measure)

Key Inclusion Criteria:

  • Have a primary diagnosis of schizophrenia
  • History of at least 1 prior episode of acute schizophrenia in the 3 years preceding screening
  • History of schizophrenia requiring continuous antipsychotic treatment for at least 1 years preceding screening
  • Clinically stable at the time of entry defined by at least a 4 week period of stable symptoms

Key Exclusion Criteria:

  • Have an uncontrolled, unstable clinically significant medical condition
  • History of suicide attempt or significant violence to others in the past 2 years
  • A substance-induced psychotic disorder or behavioral disturbance thought to be due to substance abuse
  • Current substance abuse/dependence
  • Concurrent psychiatric disorder other than schizophrenia.
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Croatia,   India,   Latvia,   Russian Federation,   Ukraine,   United States
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
October 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP